|
JP3415145B2
(ja)
|
1991-03-05 |
2003-06-09 |
ザ ウエルカム ファウンデーション リミテッド |
弱毒化細菌における組換えタンパク質の発現
|
|
US5961974A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
|
|
ES2198025T3
(es)
|
1991-10-25 |
2004-01-16 |
Immunex Corporation |
Anticuerpos contra cd40-l.
|
|
US5981724A
(en)
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
US7405270B2
(en)
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
US5962406A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
|
|
GB9202219D0
(en)
*
|
1992-02-03 |
1992-03-18 |
Connaught Lab |
A synthetic heamophilus influenzae conjugate vaccine
|
|
CA2143299A1
(en)
|
1992-09-04 |
1994-03-17 |
University Of Saskatchewan |
Novel bacterial vaccines using vaccine strains of pathogenic bacteria
|
|
WO1995014487A1
(en)
|
1993-11-24 |
1995-06-01 |
The Australian National University |
Treatment of viral disease with cd40l peptide
|
|
GB9420146D0
(en)
*
|
1994-10-06 |
1994-11-23 |
Cancer Res Campaign Tech |
Papillomavirus vaccine
|
|
ES2179187T3
(es)
|
1995-03-01 |
2003-01-16 |
Immunex Corp |
Oriteuba qye se yba a cd40 para estimular una respuesta inmune.
|
|
IL122174A
(en)
|
1995-06-07 |
2004-07-25 |
Immunex Corp |
Dna encoding a cd40l mutein and a cd40l polypeptide encoded by said dna
|
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6479258B1
(en)
|
1995-12-07 |
2002-11-12 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines
|
|
US6306387B1
(en)
|
1997-05-29 |
2001-10-23 |
The Research Foundation Of State University Of New York |
Antigen delivery system
|
|
US20030045492A1
(en)
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
CA2223225A1
(en)
|
1997-11-28 |
1999-05-28 |
Canadian Red Cross Society |
Method for inhibiting in vivo immune response
|
|
IL136731A0
(en)
|
1997-12-19 |
2001-06-14 |
Immunex Corp |
Method for reducing susceptibility to hiv infection
|
|
GB9806449D0
(en)
|
1998-03-25 |
1998-05-27 |
Peptide Therapeutics Ltd |
Attenuated bacteria useful in vaccines
|
|
US6190669B1
(en)
|
1998-05-13 |
2001-02-20 |
University Of Maryland, Baltimore |
Attenuated mutants of salmonella which constitutively express the Vi antigen
|
|
IT1299583B1
(it)
|
1998-05-19 |
2000-03-16 |
Vander Way Limited |
Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
|
|
DE69939264D1
(de)
|
1998-09-04 |
2008-09-18 |
Emergent Product Dev Uk Ltd |
Attenuierte salmonella spi2 mutante als antigen-träger
|
|
US7300774B1
(en)
|
1999-12-09 |
2007-11-27 |
The Regents Of The University Of California |
Multimeric fusion proteins of the TNF superfamily ligands
|
|
JP2003508016A
(ja)
|
1999-04-16 |
2003-03-04 |
エフ．ホフマン−ラ ロシュ アーゲー |
Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
|
|
EP1067194A1
(en)
|
1999-04-16 |
2001-01-10 |
F. Hoffmann-La Roche Ag |
Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
|
|
WO2001013948A1
(en)
*
|
1999-08-20 |
2001-03-01 |
The General Hospital Corporation |
Outer membrane protein a, peptidoglycan-associated lipoprotein, and murein lipoprotein as therapeutic targets for treatment of sepsis
|
|
WO2001026608A2
(en)
|
1999-10-14 |
2001-04-19 |
Ledbetter Jeffrey A |
Dna vaccines encoding antigen linked to a domain that binds cd40
|
|
TR200401569T4
(tr)
|
1999-12-28 |
2004-07-21 |
Akzo Nobel N.V. |
Flagelin ya da flagelle'ya karşı antikorların oluşumuna sebep olmayan salmonelle aşısı
|
|
WO2001054472A2
(en)
|
2000-01-31 |
2001-08-02 |
Human Genome Sciences, Inc. |
Nucleic acids, proteins, and antibodies
|
|
CA2399790C
(en)
|
2000-02-02 |
2012-10-30 |
Ralph A. Tripp |
Cd40 ligand adjuvant for respiratory syncytial virus
|
|
DE60112413T2
(de)
|
2000-03-17 |
2006-06-01 |
Pharmacia & Upjohn Co. Llc, Kalamazoo |
Ssa inaktivierte salmonella impfstoffe
|
|
GB0015426D0
(en)
|
2000-06-24 |
2000-08-16 |
Univ Southampton |
Method for generating soluble highly multimeric proteins
|
|
US20030165538A1
(en)
|
2000-06-26 |
2003-09-04 |
Maxygen Incorporated |
Methods and compositions for developing spore display systems for medicinal and industrial applications
|
|
AU2002221780A1
(en)
|
2000-10-31 |
2002-05-15 |
F.Hoffmann-La Roche Ag |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
US7811816B2
(en)
|
2001-05-15 |
2010-10-12 |
Ortho-Mcneil Pharmaeutical, Inc. |
Isolated CD8 +T lymphocytes specifically cytotoxic for a disease causing target cell
|
|
CN100447154C
(zh)
|
2001-05-15 |
2008-12-31 |
费因斯坦医学研究学院 |
利用hmg片段作为抗炎症试剂
|
|
US7220723B2
(en)
|
2001-05-15 |
2007-05-22 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
ITMI20011986A1
(it)
|
2001-09-25 |
2003-03-25 |
San Raffaele Centro Fond |
Metodo e composizione per l'attivazione di cellule presentanti l'antigene
|
|
DE50212280D1
(de)
|
2001-12-19 |
2008-06-26 |
Alcedo Biotech Gmbh |
Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
|
|
ES2309224T3
(es)
|
2001-12-21 |
2008-12-16 |
Immunex Corporation |
Polipeptidos recombinantes.
|
|
ATE421249T1
(de)
|
2002-02-13 |
2009-02-15 |
Immunology Lab Inc |
Zusammensetzungen und verfahren für die behandlung von mikroorganismen-infektionen
|
|
US6923958B2
(en)
|
2002-03-02 |
2005-08-02 |
The Scripps Research Institute |
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
|
|
CA2526895A1
(en)
|
2002-04-15 |
2003-11-27 |
Washington University |
Regulated attenuation of live vaccines to enhance cross protective immunogenicity
|
|
US7495090B2
(en)
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
|
US20060121047A1
(en)
|
2002-11-20 |
2006-06-08 |
Tracey Kevin J |
Use of hmgb polypetides for increasing immune responses
|
|
JP2006510619A
(ja)
|
2002-11-20 |
2006-03-30 |
クリティカル セラピューティクス，インコーポレイテッド |
抗炎症剤としてのｈｍｇｂ断片の使用
|
|
US20040141948A1
(en)
|
2002-11-20 |
2004-07-22 |
Critical Therapeutics, Inc. |
Use of HMGB fragments as anti-inflammatory agents
|
|
US20040156851A1
(en)
|
2002-11-20 |
2004-08-12 |
Critical Therapeutics, Inc. |
HMGB1 combination therapies
|
|
US20060014248A1
(en)
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
|
US20050181994A1
(en)
|
2003-01-06 |
2005-08-18 |
Xencor, Inc. |
Novel variants of CD40L protein
|
|
US7696169B2
(en)
|
2003-06-06 |
2010-04-13 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
WO2005025604A2
(en)
|
2003-09-10 |
2005-03-24 |
The General Hospital Corporation |
Use of hmgb and hmgb fragments to decrease specific immune response
|
|
EP1673389A2
(en)
|
2003-10-10 |
2006-06-28 |
Xencor Inc. |
Novel variants of cd40l protein
|
|
KR20060129229A
(ko)
|
2003-11-21 |
2006-12-15 |
에이스 바이오사이언시즈 에이/에스 |
표면에 위치한 빈창자캄필로박터 폴리펩티드
|
|
US8828957B2
(en)
|
2003-12-11 |
2014-09-09 |
Microvax, Llc |
Methods for generating immunity to antigen
|
|
CA2548347A1
(en)
|
2003-12-11 |
2005-06-30 |
Sidney Kimmel Cancer Center |
Methods for generating immunity to antigen
|
|
US20070128183A1
(en)
|
2004-04-27 |
2007-06-07 |
Intercell Ag |
Td antigens
|
|
WO2005113598A2
(en)
|
2004-05-21 |
2005-12-01 |
Xencor, Inc. |
Tnf super family members with altered immunogenicity
|
|
US20080305120A1
(en)
|
2004-06-17 |
2008-12-11 |
Medimmune, Inc. |
Immunogenic Compositions Comprising Hmgb 1 Polypeptides
|
|
WO2006012373A2
(en)
|
2004-07-20 |
2006-02-02 |
Critical Therapeutics, Inc. |
Combination therapies of hmgb and complement inhibitors against inflammation
|
|
WO2006042177A2
(en)
|
2004-10-07 |
2006-04-20 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
US8513008B2
(en)
|
2004-10-07 |
2013-08-20 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
GB0423681D0
(en)
|
2004-10-26 |
2004-11-24 |
Sec Dep For Environment Food & |
Vaccine and nucleic acids
|
|
WO2006105972A1
(en)
|
2005-04-07 |
2006-10-12 |
Universite Libre De Bruxelles |
Transgenic organism expressing cd40l and uses thereof
|
|
WO2006130525A2
(en)
|
2005-05-31 |
2006-12-07 |
Sidney Kimmel Cancer Center |
Methods for immunotherapy of cancer
|
|
WO2007011606A2
(en)
|
2005-07-18 |
2007-01-25 |
Critical Therapeutics, Inc. |
USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
|
|
AU2006301171B9
(en)
|
2005-10-07 |
2012-03-29 |
Proyecto De Biomedicina Cima, S.L. |
Immunostimulatory combination for the prophylactics and treatment of hepatitis C
|
|
EP1951862B1
(en)
|
2005-11-07 |
2013-07-24 |
MicroVAX, LLC |
Cd40 ligand fusion protein vaccine
|
|
WO2007054658A1
(en)
|
2005-11-14 |
2007-05-18 |
King's College London |
Control of immune responses
|
|
US7829097B2
(en)
|
2006-02-06 |
2010-11-09 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Use of HMGB1 for protection against ischemia reperfusion injury
|
|
CU23576A1
(es)
|
2006-02-28 |
2010-09-30 |
Ct Ingenieria Genetica Biotech |
Antígenos vacunales quiméricos contra el virus de la influenza aviar
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
US8802419B2
(en)
|
2006-03-02 |
2014-08-12 |
University Of Massachusetts |
Modified pathogens for use as vaccines
|
|
CN101064542B
(zh)
|
2006-04-30 |
2010-12-08 |
中兴通讯股份有限公司 |
Mimo ofdm系统中发射天线选择与自适应调制方法
|
|
ES2709176T3
(es)
*
|
2006-08-11 |
2019-04-15 |
Life Sciences Res Partners Vzw |
Péptidos inmunogénicos y su uso en trastornos inmunitarios
|
|
EP2586790A3
(en)
*
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogens from uropathogenic Escherichia coli
|
|
PL2066339T3
(pl)
|
2006-09-18 |
2015-02-27 |
Univ Arkansas |
Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
|
|
WO2008109825A2
(en)
|
2007-03-08 |
2008-09-12 |
Mayo Foundation For Medical Education And Research |
Inducing immune-mediated tumor cell death
|
|
WO2009059018A1
(en)
|
2007-10-30 |
2009-05-07 |
The Board Of Trustees Of The University Of Arkansas |
Compositions and methods of enhancing immune responses to flagellated bacterium
|
|
PT3097926T
(pt)
|
2007-11-01 |
2020-01-08 |
Univ Guelph |
Composições e métodos de potenciação das respostas imunitárias frente a eimeria
|
|
WO2010148541A1
(zh)
*
|
2009-06-26 |
2010-12-29 |
鑫品生医科技股份有限公司 |
含衍生自细胞巨大病毒的胜肽的免疫原组成物及使用方法
|
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
|
ES2643646T3
(es)
*
|
2010-01-21 |
2017-11-23 |
The Board Of Trustees Of The University Of Arkansas |
Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
|
|
MX350306B
(es)
*
|
2010-06-09 |
2017-09-04 |
Univ Arkansas |
Vacuna y metodos para reducir una infeccion por campylobacter.
|
|
US20140328815A1
(en)
|
2011-11-11 |
2014-11-06 |
Nutrition Physiology Company, Llc |
Lactic Acid Bacteria And Their Use As Dietary Supplementals For Poultry
|
|
CN104159601B
(zh)
|
2012-02-01 |
2017-05-24 |
代表亚利桑那大学的亚利桑那董事会 |
弯曲杆菌属免疫原性组合物及其用途
|
|
WO2014028776A1
(en)
*
|
2012-08-15 |
2014-02-20 |
Zyngenia, Inc. |
Monovalent and multivalent multispecific complexes and uses thereof
|
|
US20150297714A1
(en)
|
2012-10-29 |
2015-10-22 |
The Board Of Trustees Of The University Of Arkansas |
Novel mucosal adjuvants and delivery systems
|
|
AR094791A1
(es)
|
2013-02-14 |
2015-08-26 |
Univ Arkansas |
Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
|
|
AU2014239557B2
(en)
*
|
2013-03-15 |
2019-01-03 |
The Board Of Trustees Of The University Of Arkansas |
Compositions and methods of enhancing immune responses to enteric pathogens
|